46 results on '"Stary, J."'
Search Results
2. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
3. Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with t(6;11)(q27;q23)
4. miR-9 is a tumor suppressor in pediatric AML with t(8;21)
5. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage
6. The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS
7. Erratum: Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
8. Real-time PCR quantification of major Wilms’ tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences
9. High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome
10. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia
11. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
12. Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic
13. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring
14. T-cell receptor Vβ CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia
15. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?
16. Childhood secondary ALL after ALL treatment
17. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring
18. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
19. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity
20. Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood
21. Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia—impact on minimal residual disease detection
22. The clinical relevance of BAALC and ERG expression levels in pediatric AML
23. Transfer of genomics information to flow cytometry: expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia
24. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment
25. TEL/AML1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL
26. Treatment response and residual-disease monitoring in initial and relapsed TEL-AML1 positive childhood ALL
27. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
28. Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment
29. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage
30. miR-9 is a tumor suppressor in pediatric AML with t(8;21)
31. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS)
32. The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS
33. Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia—impact on minimal residual disease detection
34. The clinical relevance of BAALC and ERG expression levels in pediatric AML
35. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
36. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring
37. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease
38. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
39. Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency
40. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
41. ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
42. Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
43. Invasive fungal diseases impact on outcome of childhood ALL - an analysis of the international trial AIEOP-BFM ALL 2009.
44. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
45. Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation.
46. TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.